logo-loader
viewArc Minerals Limited

Ortac Resources puts focus firmly on African exploration

Ortac Resources' diversified investment portfolio will now be streamlined, with the focus on two particular assets in Africa

Gold bars
The focus is now exclusively on gold in Africa

The newly appointed board members at Ortac Resources Ltd (LON:OTC) have wasted little time in setting out the direction they want the company to go in, after passing all resolutions at the company’s annual meeting on 8th September.

Chairman Nick von Schirnding and new non-exec Brian McMaster both bring extensive mining and restructuring experience to the board and have decided that Ortac should focus exclusively on its African exploration mining assets.  

This will see Ortac progressing its core gold and copper assets in the Democratic Republic of Congo and Zambia. 

Ortac now has significant investments and board representation in respect of two operating companies, Casa Mining Ltd and Zamsort Limited.

READ: Ortac Resources highlights ‘strong position’ as it sees recovering natural resources sector

The board believes the core investments in Casa and Zamsort present the best near term opportunity for Ortac to create value for shareholders, and that this strategy will ensure a new, focused, value accretive approach going forward. 

Zambian copper opportunity

It's taken a little longer to develope than expected, but the upside at the Kalaba copper cobalt project in Zambia looks sizeable. This was a project that for years was mired in a bureaucratic log-jam from which it has only recently broken free. That explains why such a promising resource wasn't worked up further during the last boom, and why Ortac was able to build up to a 14% stake on good terms at a time when funding was more scarce. 

The plan now is to build a demonstration plant to initiate small-scale production and generate a certain amount of cashflow, before scaling up. 

Gold upside in the Democratic Republic of Congo

Ortac owns 45% of Casa Mining Ltd, which owns the Akyanga gold deposit in the Democratic Republic of Congo. This has a well-established resource of 1.05 mln ounces of gold at 2.27 grams per tonne within a wider lower-grade envelope of 1.57 mln ounces at 1.65 grams per tonne.

Exploration work remains ongoing.

A wide range of options now under consideration for other assets

The Company continues to explore a number of strategic options with respect to its Kremnica gold project in Slovakia and will now seek to divest its interest in Andiamo, an Eritrean-focussed investment company. 

In Slovakia, the Company is in constructive discussions with a number of parties, both local and international and in the interim, will keep associated expenditures to a minimum.

Chairman pleased to be talking about "clear and simple direction"

"We are pleased to be able to set out the parameters of a clear and simple direction for Ortac's future,” said chairman Nick von Schirnding. 

“This strategic focus is underpinned by two potentially highly-value accretive exploration assets in the DRC and Zambia. We believe this is the right direction for us, in order to generate near term value for the Company's investors and sets a clear path to long term sustainable growth. Both of these projects have been substantially de-risked and with near term catalysts are at exciting times in their development."

 

 

Quick facts: Arc Minerals Limited

Price: 2.8 GBX

AIM:ARCM
Market: AIM
Market Cap: £20.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 35 minutes ago

3 min read